TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
-104.00 (-2.17%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close4,801.00
Bid4,694.00 x 200
Ask4,697.00 x 34100
Day's Range4,660.00 - 4,867.00
52 Week Range38.20 - 4,867.00
Avg. Volume1,258,796
Market Cap47.72B
PE Ratio (TTM)N/A
EPS (TTM)-6.11
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & Yield1.36 (7.11%)
Ex-Dividend Date2017-03-02
1y Target Est28.00
  • SmarterAnalyst3 days ago

    Mizuho Wonders if Teva Can Avoid Downgrade to High Yield After Rocky 3Q Print

    Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the "transformative deal" needed for a core generics comeback. Next year looks possible for recovery, but what of Teva's long-term revival?

  • Market Realist3 days ago

    Taking a Deeper Look at Antares Pharma’s Financials in 2017

    Antares Pharma’s gross profit margins reached 45.0%, 57.0%, and 58.0% for fiscal 2016, fiscal 2015, and fiscal 2014, respectively.

  • Reuters4 days ago

    U.S. junk bond funds post 4th biggest week of outflows ever -Lipper

    U.S. fund investors walloped high-yield funds with their biggest week of withdrawals since March, Lipper data showed on Thursday. The "junk" bond mutual funds and exchange-traded funds posted $4.4 billion in net withdrawals during the week ended Nov. 15, the fourth largest weekly outflow on record dating to 1992. A stew of concerns hurt high-yield markets during the week, but the extensive withdrawals signal that investor sentiment may have been chief among them.

  • Teva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic Value
    Simply Wall St.4 days ago

    Teva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic Value

    Does the share price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. AnyoneRead More...

  • SmarterAnalyst4 days ago

    Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

    Billionaire Israel "Izzy" Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with volatile fire in the market: Teva Pharmaceutical (NYSE:TEVA) and Valeant Pharmaceuticals (NYSE:VRX). However, the hedge fund guru is doing away with almost all of ACADIA Pharmaceuticals (NASDAQ:ACAD), a stock that has attracted mostly bullish attention on the Street.

  • Market Realist4 days ago

    Exploring Antares Pharma’s Current Pipeline of Products

    On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.

  • Moody's4 days ago

    Health and Happiness (H&H) Int'l. Hldgs. Ltd. -- Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights

    Announcement: Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights. Global Credit Research- 16 Nov 2017. Hong Kong, November 16, 2017-- Moody's Investors Service ...

  • Why The Children's Place, Teva Pharmaceutical Industries, and Sears Holdings Jumped Today
    Motley Fool5 days ago

    Why The Children's Place, Teva Pharmaceutical Industries, and Sears Holdings Jumped Today

    Get the scoop on what sent these stocks higher.

  • Barrons.com5 days ago

    Will Teva's Pipeline Lead It to the Promised Land?

    Shares of generic and specialty drug producer Teva  Pharmaceutical (TEVA) jumped 7% Wednesday afternoon as investors get more hopeful about the future. Jefferies analysts met with Teva executives in Israel including the head of research and development, and concluded in a fresh report today that new CEO Kare Schultz may discuss strategy with investors by the end of the year, to coincide with quarterly results. Jefferies analysts David Steinberg, Edward Chung and Anthony Baldor gleaned in meetings that cost cutting and asset sales are "on the table" for Teva, with $35 billion in debt, high leverage and weakening profitability over time.

  • Business Wire5 days ago

    Teva Announces Prescription Copay Savings Program for Generic Gleevec® Tablets in the United States

    Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch of a prescription copay assistance program in the U.S.

  • The Wall Street Journal5 days ago

    [$$] Foundation Consumer Healthcare Buys Plan B One-Step From Teva

    In support of the $675 million deal, Greg Bradley joined Foundation Consumer Healthcare as president and chief executive.

  • SmarterAnalyst5 days ago

    Cantor Continues to Play It Cautious on Teva Following Management Meeting

    Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove themselves, before the Israeli pharma giant can make a comeback- at least in the eyes of Cantor analyst Louise Chen.

  • SmarterAnalyst6 days ago

    Oppenheimer Discouraged on Teva’s Ability to Generate Gains in the Short-Term

    Is Teva Pharmaceutical (NYSE:TEVA) overpriced? For a company that just released a third quarter print, Oppenheimer analyst Derek Archila does not have any sense of improved conviction on the beleaguered biotech giant's growth arc.

  • Moody's6 days ago

    Triton (European Loan Conduit No. 26) PLC (ELoC 26) -- Moody's assigns B2 CFR to IWH UK Finco Limited

    Rating Action: Moody's assigns B2 CFR to IWH UK Finco Limited. Global Credit Research- 14 Nov 2017. London, 14 November 2017-- Moody's Investors Service, has today assigned a B2 Corporate Family rating ...

  • Reuters7 days ago

    Allergan to sell a quarter of its Teva stake in first quarter 2018

    Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker. Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co unit - acting as a dealer for the shares - sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.

  • Benzinga7 days ago

    For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA )'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. ...

  • Barrons.com7 days ago

    Teva: It's Never Too Late to Sell

    It was just two months ago that Teva Pharmaceutical Industries (TEVA) hired Kare Schultz as its new CEO, ending months of speculation about who would be tasked to steer the troubled specialty drug maker. Yes, hiring Schultz was a good move, Schott says. While Teva’s recent appointment of Kare Schultz as President and CEO (joined Nov 1) represents a clear positive in our view, adding a highly creditable executive with significant industry experience, we do not see any quick fixes for Teva... Overall, we believe Kare Schultz has the right background/experience set to evaluate and execute on restructuring opportunities in the Teva portfolio having successfully implementing a two-year restructuring program at Lundbeck with cost reductions exceeding expectations.

  • MarketWatch7 days ago

    Teva's stock drops after J.P. Morgan downgrades to rare bearish rating

    Shares of Teva Pharmaceutical Industries Ltd. shed 2.2% in premarket trade Monday, after the generic drug maker was downgraded at J.P. Morgan to a rare bearish rating, citing concerns over the U.S. generics ...

  • SmarterAnalyst12 days ago

    Teva Pharmaceutical Is Getting a Beating Between Analysts and Credit Rating Agencies Who See Valuation Heading Down the Drain

    Teva Pharmaceutical (NYSE:TEVA) investors have seen a once strong Israeli pharma giant stumble 71% from its former valuation glory, and some on the Street fear another 50% fall from grace is still coming investors' way. HSBC  analyst Steve McGarry and Wells Fargo analyst Davis Maris prepare for the worst.

  • MarketWatch12 days ago

    Teva’s stock and bonds walloped after Fitch downgrade to junk

    Teva Pharmaceutical Industries’s stock slid 6% and its bonds dropped several points Tuesday, after Fitch Ratings downgraded the credit to junk, following disappointing earnings last week.

  • Barrons.com13 days ago

    Why Teva Pharma Could Fall Another 50%

    Late yesterday, Fitch cut Teva’s debt rating to junk, making it the first of the three major credit ratings agencies to strip the generic drug maker of its investment-grade status. According to, HSBC analyst Steve McGarry cut his rating on the stock to a Reduce and slashed his price target on the stock from $26 a share to $6 a share, arguing that the drug maker’s balance sheet is “over-stretched”. In short, McGarry sees Teva’s U.S.-listed shares falling another 50% in the next year, having already lost 71% over the past 12 months.

  • SmarterAnalyst13 days ago

    Wall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price Target

    The market has divided itself into two camps. The bulls argue that the worst is behind Teva Pharmaceutical (NYSE:TEVA) as it started focusing on getting the business growing again. The bears argue that the market is too optimistic about Teva's recovery, which could take a long, long time. Goldman Sachs analyst Jami Rubin has found himself in the middle.

  • Barrons.com13 days ago

    Teva Pharma: Junk Rating Adds to Woes

    Generic drug prices are falling in the U.S. The company has a pile of debt from its 2016 acquisition of Actavis’s generic drug business. Add it all together and it’s a recipe for a junk credit rating...or at least the analysts at Fitch Ratings think so. Late yesterday, the firm became the first of the three major credit ratings agencies to cut Teva’s debt rating to junk, downgrading the drug maker to BB from BBB- with a negative outlook.

  • TheStreet.com13 days ago

    Teva's Stock Could Crash Another 50% After Debt Cut to Junk

    Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.

  • TheStreet.com13 days ago

    Teva Pharmaceuticals Ratings Cut at Fitch

    The ratings downgrade was predicated on concerns encompassing Teva's current debt.